Wen Q H, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H
Department of Oto-Laryngology, School of Medicine, Kanazawa University, Ishikawa, Japan.
Laryngoscope. 1996 Jul;106(7):884-8. doi: 10.1097/00005537-199607000-00019.
The purpose of this study was to determine the overexpression of both epidermal growth factor receptor (EGFR) and transforming growth factor-alpha (TGF-alpha) (a ligand of EGFR) in early laryngeal squamous cell carcinoma. In addition, we attempted to evaluate the prognostic values of our findings. Expression of EGFR and TGF-alpha in tumor tissue was examined immunohistochemically in 68 patients who had been treated with radiotherapy for early laryngeal cancer. Overexpression of the two factors was noted in 42.6% and 55.9%, respectively. No significant differences due to age, tumor size, and location or grade of cancer tissues were seen. Higher survival rates, found in patients with EGFR (-) and TGF-alpha (-) tumors as compared with those with EGFR (+) and TGF-alpha (+) (97.4%, 100% and 86.2%, 86.8%, respectively), were not statistically significant. The recurrence rates were similar between EGFR (+) and EGFR (-) (37.9% and 35.9%, respectively). However, the recurrence rate in patients with TGF-alpha (+) was significantly higher (57.9%) than in those with TGF-alpha (-) (10%; P<.01). Therefore overexpression of TGF-alpha may be an important indicator for recurrence in patients with early laryngeal squamous cell carcinoma treated by irradiation.
本研究的目的是确定表皮生长因子受体（EGFR）和转化生长因子-α（TGF-α，EGFR的一种配体）在早期喉鳞状细胞癌中的过表达情况。此外，我们试图评估我们研究结果的预后价值。对68例接受早期喉癌放射治疗的患者的肿瘤组织进行免疫组织化学检查，以检测EGFR和TGF-α的表达。两种因子的过表达分别为42.6%和55.9%。在年龄、肿瘤大小、位置或癌组织分级方面未发现显著差异。与EGFR（+）和TGF-α（+）的患者相比，EGFR（-）和TGF-α（-）肿瘤患者的生存率较高（分别为97.4%、100%和86.2%、86.8%），但无统计学意义。EGFR（+）和EGFR（-）患者的复发率相似（分别为37.9%和35.9%）。然而，TGF-α（+）患者的复发率（57.9%）显著高于TGF-α（-）患者（10%；P<0.01）。因此，TGF-α的过表达可能是接受放疗的早期喉鳞状细胞癌患者复发的一个重要指标。
